Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.

Antimicrobial Agents and Chemotherapy
Seth T HousmanDavid P Nicolau

Abstract

This study assessed the pulmonary disposition of tedizolid, an oxazolidinone, in adult volunteers receiving 200 mg of the prodrug tedizolid phosphate orally every 24 h for 3 days to steady state. Plasma samples were collected over the dosing interval, and participants were randomized to undergo bronchoalveolar lavage (BAL) at 2, 6, 12, or 24 h after the last dose. Drug concentrations in plasma, BAL fluid, and alveolar macrophages (AM) were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS), and the urea correction method was used to calculate epithelial lining fluid (ELF) concentrations. Pharmacokinetic parameters were estimated by noncompartmental methods followed by compartmental population pharmacokinetics. Penetration was calculated as the area under the concentration-time curve during the dosing interval (AUC(0-24)) for ELF and AM relative to the free AUC(0-24) (fAUC(0-24)) in plasma. The half-life and volume of distribution in plasma were 9.23 ± 2.04 h and 108.25 ± 20.53 liters (means ± standard deviations), respectively. Total AUC(0-24) in plasma was 25.13 ± 5.78 μg · h/ml. Protein binding was 89.44% ± 1.58%, resulting in a mean fAUC(0-24) of 2.65 ± 0.72 μg · h/ml in plasma. Mean concentrations (μg/m...Continue Reading

References

Apr 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·K YamaokaT Uno
Feb 1, 1995·Antimicrobial Agents and Chemotherapy·J E ConteE Zurlinden
Nov 1, 1996·Antimicrobial Agents and Chemotherapy·K M OlsenG D Campbell
Jun 1, 1997·Antimicrobial Agents and Chemotherapy·K A RodvoldR J Servi
Dec 10, 1999·Clinical Pharmacokinetics·K A Rodvold
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E RubinsteinUNKNOWN Linezolid Nosocomial Pneumonia Study Group
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·John E ConteElisabeth Zurlinden
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Keith A RodvoldMark H Gotfried
Dec 20, 2003·Lancet·Thomas M File
Jan 5, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R Monina KlevensUNKNOWN National Nosocomial Infections Surveillance System
Sep 12, 2007·Antimicrobial Agents and Chemotherapy·Sungmin Kiem, Jerome J Schentag
Jan 24, 2009·The Journal of Antimicrobial Chemotherapy·David M LivermoreNeil Woodford
Feb 17, 2009·The Journal of Antimicrobial Chemotherapy·Ronald N JonesMariana Castanheira
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ronald N Jones
Jan 7, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine LiuUNKNOWN Infectious Diseases Society of America
Sep 14, 2011·Antimicrobial Agents and Chemotherapy·Thomas P LodiseKeith A Rodvold

❮ Previous
Next ❯

Citations

Dec 18, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas P Lodise, G L Drusano
Dec 18, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jeffrey B LockeKenneth Bartizal
Apr 17, 2013·Drug Design, Development and Therapy·Olatz UrbinaSantiago Grau
Jul 24, 2013·Expert Opinion on Pharmacotherapy·Jeffrey M RybakMichael J Rybak
Oct 13, 2015·Expert Opinion on Drug Metabolism & Toxicology·Antonios DourosRalf Stahlmann
Jan 9, 2013·Expert Opinion on Drug Metabolism & Toxicology·Xin LiuMichael S Roberts
Dec 3, 2015·Pharmaceutical Research·Pyry A J VälitaloJ G Coen van Hasselt
Oct 1, 2014·Pharmacotherapy·Jeffrey M RybakCraig A Martin
Mar 22, 2016·Expert Opinion on Investigational Drugs·Vicenç FalcóBenito Almirante
Jun 25, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Steven D Burdette, Robin Trotman
Mar 3, 2015·International Journal of Antimicrobial Agents·Joseph L Kuti, David P Nicolau
Feb 25, 2015·Infectious Diseases and Therapy·Jeffrey M Rybak, Karrine Roberts
Mar 17, 2016·Expert Opinion on Drug Metabolism & Toxicology·Dario CattaneoMichael Neely
Oct 22, 2014·Antimicrobial Agents and Chemotherapy·Shawn FlanaganPhilippe Prokocimer
Feb 1, 2017·Expert Opinion on Drug Metabolism & Toxicology·Darrell McBrideMichael J Durkin
Jul 22, 2017·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuaki TakedaKatsunori Yanagihara
Jan 31, 2018·Antimicrobial Agents and Chemotherapy·Matthieu GrégoireWilliam Couet
Oct 25, 2017·Clinical Pharmacokinetics·Claire RogerLaurent Muller
Dec 6, 2014·Hospital Pharmacy·Dennis J CadaDanial E Baker
Jun 20, 2018·Antimicrobial Agents and Chemotherapy·A Young J ParkPaul M Beringer
Nov 30, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Devyani DeshpandeTawanda Gumbo
Nov 30, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shashikant SrivastavaTawanda Gumbo
Apr 2, 2014·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jamie J KisgenLindsey M Childs
Jan 22, 2019·Current Opinion in Infectious Diseases·Elda RighiMatteo Bassetti
May 17, 2019·Expert Opinion on Pharmacotherapy·Ana MotosAntoni Torres
Jan 26, 2018·Pharmaceutical Research·Linda B S AulinJ G Coen van Hasselt
Aug 21, 2019·Microorganisms·Despoina KoulentiUNKNOWN SotiriosTsiodras
Dec 31, 2019·The Journal of Antimicrobial Chemotherapy·Mike Marvin RuthJakko van Ingen
May 26, 2020·Expert Review of Clinical Pharmacology·Alberto A Carena, Martin E Stryjewski
Sep 20, 2017·The Journal of Antimicrobial Chemotherapy·Devyani DeshpandeTawanda Gumbo
Sep 20, 2017·The Journal of Antimicrobial Chemotherapy·Devyani DeshpandeTawanda Gumbo
Nov 19, 2019·Frontiers in Pharmacology·Yang LiuBirong Dong

❮ Previous
Next ❯

Software Mentioned

SYSTAT
ADAPT
WinNonlin

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.